Navigation Links
Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results
Date:10/22/2010

BALTIMORE, Oct. 22 /PRNewswire/ -- Pharmaceutical company Pharmaxis (ASX: PXS) today announced significant results of pooled data from its two large scale six month Phase III trials of Bronchitol (inhaled mannitol) in people with cystic fibrosis.

The combined results have been presented for the first time at the North American Cystic Fibrosis Conference (NACFC) currently underway in Baltimore.  In addition, more results from the second trial (CF302) have been released to supplement the top line results reported on 22nd June 2010.

The two studies were of similar design and encompass 643 patients from 11 countries.  Over the 26 weeks of the two studies, patients treated with Bronchitol had an average 7.3% improvement in lung function (FEV1) compared to baseline (p<0.001) and a highly significant improvement compared to patients in the control group (p<0.001).  In the sub group of patients who were also on rhDNase, patients taking Bronchitol showed a 5.3% improvement from baseline (p<0.001), that was again superior to the control group (p=0.020).  In the sub group of patients who were not on rhDNase, patients taking Bronchitol showed a 9.44% improvement from baseline (p<0.001), that was also superior to the control group (p=0.009).  The overall rate per annum reduction in exacerbations for patients on Bronchitol versus those on control was 25% (NS) and the number of patients experiencing an exacerbation was 29% lower for those taking Bronchitol (NS). This result was achieved in a well treated patient population who overall had a very low rate of exacerbations in the study.

"This comprehensive analysis of the pooled results provides an important insight into the overall benefits Bronchitol can provide to patients who are receiving current best standard of care," said Pharmaxis Chief Executive Officer Dr. Alan Robertson.  "The number of exacerbations in the two studies was fairly low, reflecting the aggres
'/>"/>

SOURCE Pharmaxis
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Pharmaxis ARIDOL™ (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
2. Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
3. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
4. Pharmaxis Announces New Drug Application Submission for Aridol(TM)
5. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
6. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
7. Pharmaxis Establishes Named Patient Program for Bronchitol
8. Pharmaxis Long-Term Safety Study of Bronchitol Completes
9. Boston Scientific Announces CE Mark Approval for Expanded Indication of WallFlex® Biliary RX Stent
10. Warner Chilcott Announces FDA Approval of New Oral Contraceptive
11. Repligen Announces Conference Call of Second Quarter Fiscal Year 2011 Results Tuesday, November 2nd, 3:00 p.m. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Pharmacyclics, Inc. (the "Company") (Nasdaq: ... Journal of Medicine ( NEJM ) published results ... Bruton,s tyrosine kinase (BTK) inhibitor ibrutinib in patients with ... ibrutinib may be effective and generally well-tolerated in patients ... separate study examining the safety and efficacy of ibrutinib ...
(Date:6/19/2013)... BRAINTREE, Mass. , June 19, 2013 /PRNewswire/ ... announced several important developments in the pursuit of ... (Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) , ... SANM ) for the future production of medical ... , Massachusetts. Sanmina is a leading global provider of ...
(Date:6/19/2013)... 2013 /PRNewswire-iReach/ -- Robert M. Bernstein, M.D., ... procedures and founder of Bernstein Medical – Center ... Doctors, issue of New York Magazine for the ... ) Dr. Bernstein earned his ... reputation as world-renowned hair restoration physician, through a ...
Breaking Medicine Technology:Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 2Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 3Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 4Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 5Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 6Haemonetics Announces Next Steps in Manufacturing Transformation 2Haemonetics Announces Next Steps in Manufacturing Transformation 3Haemonetics Announces Next Steps in Manufacturing Transformation 4Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 2Dr. Robert Bernstein in NY Magazine's 'Best Doctors' Issue for 14th Consecutive Year 3
... 27 Kinex Pharmaceuticals will present results from a Phase ... Meeting in Orlando, on May 29, 2009. The study ... (RPCI) and Fox Chase Cancer Center. Dr. Alex Adjei, ... "Results of a phase I trial of KX2-391, a novel ...
... Administered in Dual Cord Blood Transplant for Hematologic MalignancyLA JOLLA, ... announced today that the first patient has been treated ... molecule Stem Cell Modulator (SCM) designed to increase hematopoietic stem ... pathways that guide cell fate. The study, which is ...
Cached Medicine Technology:Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 2Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 3Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support 4
(Date:6/19/2013)... Santiago, Chile (PRWEB) June 20, 2013 ... Chile Montaña has put together their winter season ... of outdoor adventure day trips in and around Santiago ... lead trips into Chile's Central Andes for backcountry skiing, ... , For those who have always dreamed of ...
(Date:6/19/2013)... (PRWEB) June 20, 2013 Everyone is looking for ... and inexpensive way to do so. It is called Skin ... - only 5 minutes per day - to improve health and ... improves general health. How? , Skin Brushing improves general health ... it aids the lymphatic system to drain toxins , ...
(Date:6/19/2013)... CA (PRWEB) June 19, 2013 Paleo Burn ... thousands of people finally sculpt the body they desire with ... other fat loss programs and health food products, Ken Smith ... and finally give consumers an easy, automatic, and permanent solution ... all the details . , After a quick review of ...
(Date:6/19/2013)... Brand new Hypertrophy Max bonus just released by Vince Del Monte ... Max program. Vince and Ben are only making this bonus ... must act quickly. , What is the all new Hypertrophy Max ... 12 month all access pass to the Live Large TV program ... TV is a Monday night show where over 4,000 members from ...
(Date:6/19/2013)... Shreya Rangarajan of Roland Park Country ... on the future of medicine. , Today, Brandeis ... Summit on the Future of Medicine and has selected ... the state of Maryland at the Summit. , "The ... an environment hard to imagine just a few years ...
Breaking Medicine News(10 mins):Health News:Chile Montaña Announces Winter Season Santiago Day Trips 2Health News:Chile Montaña Announces Winter Season Santiago Day Trips 3Health News:A Fast and Fun Way to Better Skin Quality and Overall Health, says Sublime Beauty® 2Health News:Paleo Burn Review Released by TotalWellnessCleanse.net 2Health News:New Hypertrophy Max Bonus Just Released and Only Available for 24 Hours 2Health News:Global Youth Summit on The Future of Medicine-Shreya Rangarajan selected to represent Roland Park Country School and The State of Maryland 2Health News:Global Youth Summit on The Future of Medicine-Shreya Rangarajan selected to represent Roland Park Country School and The State of Maryland 3
... wonder fish medicine for asthma patients began here Thursday amid ... of people were seen standing in queues for their turn ... offering by Bathini Goud family to avoid any controversy. ... cure for asthma, began at 3.42 p.m., the time fixed ...
... Intel has decided to extend its innovation beyond manufacturing ... to team up with other medical and healthcare companies’ ... and seven others have joined hands to enable high-end ... Health Alliance, led by Intel will seek to effectively ...
... longest working hours in Europe - a reason that is ... study //. ,Stress expert Cary Cooper, of Lancaster University, ... their negative effect on men's health, particularly those working in ... of the Daily Mail. ,Researchers studied 2,200 men ...
... be now treated by a new approach involving release ... with mice by scientists // at John Hopkins Institute ... Medicine. ,The discovery by researchers in Hopkins' ... Genetic Medicine reveals that a protein called GCN5 is ...
... common BP medication during first trimester of pregnancy have ... The Food and Drug Administration reports from data collected ... ,The study, led by William Cooper, M.D., M.P.H., associate ... Hospital at Vanderbilt, found infants born to mothers who ...
... Rajasthan man who has pledged not to marry till he passes ... a wife. He has failed in the examination yet again! // ... Behror town, over 140 km from here, has been taking the ... years of his life, he vowed to marry only after getting ...
Cached Medicine News:Health News:Administration of Fish Drug for Asthma Patients Begins in Andhra 2Health News:Diabetes - New Treatment Approach At John Hopkins 2Health News:Birth Defects Link With ACE Inhibitor Use, FDA Reports 2
Intended for the quantitative determination of magnesium in serum or plasma. Reaction: Endpoint. Wavelength: 520 nm. Linearity: 6.0 mg/dL (2.5 mmol/L)....
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution....
For the quantitative determination of total glucose in serum....
Glucose reagent is used for the quantitative determination of glucose in human serum....
Medicine Products: